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Role of recombinant factor VIIa in the treatment
of intractable bleeding in vascular surgery
Igor B. Koncˇar, MD, Lazar B. Davidovic´, PhD, Nebojs˘a Savic´, MD, Radomir B. Sinelic´, PhD,
Nikola Ilic´, MD, Marko Dragas, MD, Miroslav Markovic, PhD, and Dusan Kostic, PhD, Belgrade, Serbia
Background: Most recent publications have shown that the recombinant form of activated factor VII (rFVIIa;
NovoSeven, Novo Nordisk A/S, Bagsværd, Denmark) induces excellent hemostasis in patients with severe intrac-
table bleeding caused by trauma and major surgery. The purpose of this study was to determine the influence of
rFVIIa on the treatment of intractable perioperative bleeding in vascular surgery when conventional hemostatic
measures are inadequate.
Materials and Methods: There were two groups of patients: the NovoSeven group (group N), 10 patients with ruptured
abdominal aortic aneurysms (RAAAs) and 14 patients operated on due to thoracoabdominal aortic aneurysms (TAAAs);
the control group (group C), 14 patients with RAAAs and 17 patients with TAAAs. All patients suffered intractable
hemorrhage refractory to conventional hemostatic measures, while patients from group N were additionally treated with
rFVIIa.
Results: Postoperative blood loss was significantly lower in group N treated with rFVII (P < .0001). Postoperative
administration of packed red blood cells, fresh frozen plasma, and platelets was lower in patients from group N, (P <
.0001). Successful hemorrhage arrest was reported in 21 patients (87.5%) treated with rFVIIa, and in 9 patients (29.03%)
in group C (P < .001). Thirty-day mortality in these two groups significantly differed. The mortality rate was 12.5% (3
patients) in group N and 80.65% (25 patients) in group C (P < .0001).
Conclusion: Our findings suggest that rFVIIa may play a role in controlling the intractable perioperative and postoper-
ative bleeding in surgical patients undergoing a repair of RAAAs and TAAAs. Certainly, prospective randomized trials are
necessary to further confirm the efficacy and cost-effectiveness of rFVIIa in these patients. ( J Vasc Surg 2011;53:
1032-8.)
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lThe most common cause of intraoperative hemorrhage
is mechanical bleeding from surgically correctable sites.
Surgical bleeding is usually localized, and is manifested by a
visible jet. On the other hand, bleeding due to coagulopa-
thy, termed intractable bleeding, is often diffuse and it is
manifested as slow ooze that is difficult to control by local
measures. Intractable bleeding during the operation and in
the early postoperative period remains a significant problem
that complicates extensive vascular procedures, such as
repair of ruptured abdominal aortic aneurysms (RAAAs) and
thoracoabdominal aortic aneurysms (TAAAs). Various mech-
anisms are thought to be implicated in this coagulopa-
thy.1-3 Blood loss cause platelet and clotting factor con-
sumption, while prolonged operative time (causing heat
loss to the environment), global hypoperfusion, and
intraoperative replacement of large volumes of non-
warmed fluids are factors causing hypothermia. Hypo-
perfusion due to supraceliac aortic cross-clamping and
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1032ubsequent bowel and liver reperfusion after unclamp-
ng, induce fibrinolysis and acidosis. Both hypothermia
nd acidosis may contribute to clotting factor dysfunc-
ion. It is the interaction of these mechanisms that results
n intractable postoperative bleeding and, therefore, the
reatment of this severe complication demands a combi-
ation of various measures. These include blood trans-
usion, correction of hypothermia (by body warming,
armed fluid infusion, and local warming of surgical field),
nd application of antifibrinolytic drugs (aminocaproic acid,
ranexamic acid, and 1-Deamino-8-d-arginin vasopressin
DDAVP]), in patients with platelet dysfunction.4 How-
ver, occasionally, all these interventions are not suffi-
ient to control bleeding.
The recombinant form of activated factor VII (rFVIIa)
s a prohemostatic drug approved for use in patients with
emophilia who develop antibodies to FVIII or FIX.5,6
hemost recent studies have shown that rFVIIa (NovoSeven;
ovo Nordisk A/S, Bagsværd, Denmark) may produce an
xcellent hemostatic effect in patients with severe nonhemo-
hilic bleeding caused by trauma,7-9 cardiac,1-3,10,11 and ma-
or orthopedic surgery.12,13 However, the literature on the
se of rFVIIa in major vascular surgical procedures is
ainly anecdotal,14-19 as available data are part of larger
tudies on mixed groups of patients, case series, and re-
orts. However, the lack of controlled trials is a major
imitation of these studies.
The purpose of the present study was to determine the
ossible effects of rFVIIa on intractable perioperative
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Volume 53, Number 4 Koncˇar et al 1033bleeding in vascular surgery, when conventional hemostatic
measures were inadequate.
MATERIALS AND METHODS
At the Clinic for Vascular Surgery of the Serbian Clin-
ical Center, from January 1995 to January 2008, 723
patients were operated on for RAAAs (599) and TAAAs
(124). Of these patients, 55 (7.60%) suffered massive peri-
operative (intraoperative and/or postoperative) bleeding
with consecutive consumptive coagulopathy. To evaluate
the clinical effectiveness of rFVIIa, we compared two
groups of patients who were operated on for RAAAs and
TAAAs and had intractable bleeding. In Serbia, the appli-
cation of rFVIIa for clinical use in patients with intractable
hemorrhage in vascular surgery was approved in 2003.
Since then, this drug is routinely used in all patients who
have intractable surgical bleeding when conventional mea-
sures are inadequate. Therefore, the first group of patients
(the NovoSeven group [group N]) was gathered prospec-
tively, from July 2003 to January 2008, from 376 patients
who were operated on for either RAAAs (292 of 376
patients) or TAAAs (84 of 376 patients). This group con-
sisted of 24 patients who suffered massive perioperative
bleeding. Fourteen patients (58; 3%) were operated on for
RAAAs, while 10 patients (41; 7%) were treated for elective
TAAAs. The patients from group N have already been
reported on by our group in 2008 as part of a bigger case
series in a journal in a local language.19 In the present
study, we went further to compare the group of patients
treated with rFVIIa with the historical group of patients
who suffered from the same complication.
As a control group (group C), we considered all 31
patients with intractable bleeding that were operated on for
RAAAs (17 of 307 patients) and TAAAs (14 of 40 patients)
from January 1995 to July 2003 in the 8-year period when
rFVIIa was not available.
Group N was comprised of 23 men (95.83%) and 1
woman (4.17%), whereas group C was comprised of 27
men (87.10%) and 4 women (12.90%). The mean age in
group C was 68.58 years old, whereas in group N it was
62.9 years old. Clinical data of both groups are shown in
Table I.
Inclusion criteria for both groups were the same: sur-
gery for RAAAs or TAAAs type III or IV, massive blood
loss (defined as intraoperative blood loss of more than 50%
of circulatory volume or postoperative drainage with esti-
mated blood loss of total circulatory volume in 24 hours),
intraoperative usage of the cell saver, and the use of all
Table I. Clinical data of group C and group N
Variable Group C Group N P value
Men 27 (87.10%) 23 (95.83%) .37
Women 4 (12.90%) 1 (4.17%)
Age (years) 68.58  7.86 62.91  10.3 .0246; .07a
aFisher exact two tailed test.conventional hemostatic measures. The only inclusion cri- merion for patients from group N was the treatment with
FVIIa.
Exclusion criteria were patients who had preoperative
nticoagulant therapy or pre-existing congenital or ac-
uired coagulopathy and patients re-operated on to control
urgical bleeding.
In patients with RAAAs, urgent midline laparotomy
nd supraceliac aortic cross-clamping were performed, fol-
owed by aortic repair with tube or bifurcated graft, de-
ending on the distribution of aneurysmal disease.20,21
epair of type III TAAAs was performed through a thoraco-
hreno-laparotomy, whereas in cases of TAAA type IV, the
eft retroperitoneal approach with eleventh rib excision was
sed. During resection of TAAAs, it was necessary to
eimplant the visceral arteries, whereas in case of type III
AAAs, additional reattachment of intercostal arteries was
erformed. The cell saver was routinely used in all proce-
ures. Before aortic cross clamping, heparin 100 iu per
ilogram of body mass was routinely administered intrave-
ously. After aneurysm resection and restitution of arterial
irculation, conventional hemostatic measures were ap-
lied: reversal of heparin with protamine (according to
ody mass and time passed after total distribution of hep-
rin), transfusion of blood products and cryoprecipitate,
ocal surgical hemostatic (Surgicel; Ethicon, Inc, Johnson
Johnson, New Brunswick, NJ), and correction of acido-
is and hypothermia. We also used antifibrinolytic agents
nd procoagulant drugs, such as tranexamic acid and epsilon-
minocaproic acid, and 1-Deamino-8-d-arginin vasopressin
DDAVP) in patients with consumptive coagulopathy or
latelet dysfunction.4 Since 2003, in all patients with mas-
ive intraoperative bleeding, the standard protocol of ad-
inistering rFVIIa was used, which consisted of adminis-
ration of rFVIIa in a single bolus of 5 mL of NovoSeven
50-76 mg/kg, depending on the patients’ body weight).
n 2 patients, one more dose was added, due to inadequate
ffect of single bolus. Before administration of rFVIIa,
latelet count (50 109/L), fibrinogen level (1 g/L),
nd electrolytes disturbance (pH 7.2) were corrected.
Average temperature in the operating room was 18°C
nd 24°C in the intensive care unit. In all patients, body
emperature was measured by nasopharyngeal tube.
Intraoperative blood loss was measured by using a
anister with the volume recorded, while postoperative
rainage was measured in a calibrated drain sac. Blood from
ponges and pads was extracted into the container and
spirated into the canister, while blood loss into the oper-
ting drapes could not be counted. The drains were placed
n the Douglas cavity and retroperitoneal hematoma in the
ases of RAAAs, or in the thoracic cavity, retroperitoneal
pace close to the aneurysmatic sac, and nearby visceral and
istal anastomosis, in the cases of TAAAs. Postoperative
lood loss was measured after application of all hemostatic
easures in group C, and after treatment with all hemo-
tatic measures together with rFVIIa in group N.
We referred to the bleeding as intractable when there
as general ooze in the operative field in the absence of
ajor arterial bleeding, in the case of postoperative onset of
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April 20111034 Koncˇar et alanemia or hypotension, and an increased drainage rate in
the wound suction drains, with laboratory parameters
showing coagulopathy (increased prothrombin time and
international normalized ratio [INR]). The decision to
administer rFVIIa in group N was made in cases with
massive intractable perioperative hemorrhage, when intra-
operative blood loss was more than 50% of total blood
volume (TBV) and/or when postoperative drainage was
estimated as a blood loss of complete circulatory volume
during 24 hours.22-24
After intraoperative data, we recorded intraoperative
blood loss, the amount of blood product administration—
fresh frozen plasma (FFP), packed red blood cells (PRBC),
and cryoprecipitate and platelet concentrate (Table II).
In addition, after postoperative data were measured,
postoperative blood loss, the amount of blood product
administration—FFP, PRBC, cryoprecipitate and platelet
concentrate, and the amount of postoperative drainage
(Table III). Prothrombin time and INR were measured
preoperatively, 30 minutes and 2 hours after reversal of
heparin and administration of prohemostatic drugs, and 30
minutes and 2 hours after administration of rFVIIa in
group N (Table IV).
Intraoperative, postoperative, and total blood loss were
expressed in proportion to TBV, as blood loss (mL)/TBV
(mL) and drained blood per hour (mL)/TBV (mL). TBV
Table II. Intraoperative data
Variable Group C Group N P value
Body weight (kg) 77.61  9.03 83.08  9.44 .0334
TBV (mL)a 5430  680 5810  650 .0431
IO blood lossb 1.07  0.44 1.26  0.45 .1239
PRBC (mL) 1830  986 1541  619 .2141
FFP (mL) 1716  1259 1208  522 .0207
Platelets (mL) 133  87 294  166 .000183
FFP, Fresh frozen plasma; IO, intraoperative; PRBC, packed red blood cells;
TBV, total blood volume.
aTBV (mL) was counted by using Travenol’s total blood volume predictor
designed by Harry F. Weisberg (Travenol Laboratories, Inc, Morton Grove,
Ill).
bIntraoperative blood loss is reported as a ratio with TBV blood loss
(mL)/TBV (mL).
Table III. Postoperative data
Variable Group C Group N P value
PO blood lossa 0.18  0.11 0.06  0.07 .0257
PRBC 1346  401 593  263 .0001
FFP 1129  312 433  247 .0001
Platelets 361  209 110  107 .0001
Total blood lossb 1.24  0.45 1.32  0.45 .0592
FFP, Fresh frozen plasma; PRBC, packed red blood cells; TBV, total blood
volume.
aPostoperative blood loss is reported as a ratio with TBV - amount of blood
per hour (mL)/TBV (mL) in calibrated drain sac.
bTotal blood loss was counted as the sum of intraoperative and postoperative
blood loss and reported as a ratio with TBV.was estimated for every patient according to Travenol’s lurface area calculator and TBV predictor designed by
arry F. Weisberg (Travenol Laboratories, Inc, Morton
rove, Ill).
The main end points of the study were survival or
eath.
We made comparisons between groups N and C re-
arding parameters that express intraoperative and postop-
rative blood loss and blood product administration, INR
alue, bleeding tendency, and outcome. Statistical analysis
as made by t test, Pearson’s 2 test, Fischer exact two-
ailed test, Mann-WhitneyU test, Kruskal-Wallis analysis of
ariance (ANOVA), non-parametric test, and logistic re-
ression analysis, depending on data compared. Mean and
D values were reported for continuous data with normal
istribution. Difference was significant when P  .05.
ESULTS
Patients from group C were significantly older (P 
024), but univariate analysis revealed that it was not asso-
iated with survival (P  .07).
The two groups did not differ in the gender distribu-
ion and the surgical diagnosis (P  .05).
Intraoperative results. There was no significant dif-
erence between the groups in terms of intraoperative
lood loss (P  .1239), or intraoperative transfusion of
RBCs (P  .2141). There was a significant difference in
erms of intraoperative transfusion of FFP (P .0207), and
egarding intraoperative transfusion of platelets (P 
000183; Table II). Univariate analysis revealed that trans-
usion of FFP was not associated with survival, while platelet
ransfusion was significantly associated with survival (P  .04).
owever, multivariate analysis revealed that platelet trans-
usion had no association with survival (P  .11).
Postoperative results. Patients from group N had
ignificantly lower postoperative blood loss (P  .0257),
ostoperative transfusion of PRBC (P .0001), postoper-
tive transfusion of FFP (P  .00001), and postoperative
ransfusion of platelets (P .0001; Kruskal-Wallis ANOVA
onparametric test). Total blood loss (expressed as a ratio
f TBV) was 1.24 among patients in group C and 1.32 in
roup N (P  .0592; Table III). Multivariate analysis
evealed that these parameters did not have influence on
urvival rates (P  .05); nevertheless, postoperative blood
able IV. Prothrombin time and INR were measured
reoperatively
ariable Group C Group N P value
reoperative INR 1.10  0.15 1.06  0.17 .13
NRa 1.92  0.29 1.85  0.47 .3181
NR30 1.82  0.30 1.19  0.26 .0001
NR 120 1.60  0.23 1.11  0.24 .0001
NR, International normalizing ratio.
Postoperative INR after reversal of Heparin with protamine; INR30, inter-
ational normalizing ratio 30 minutes after administering hemostatic drugs
ncluding rFVIIa in group N; INR120, international normalizing ratio 120
inutes after administering hemostatic drugs including rFVIIa in group N.oss significantly influenced survival (P  .02).
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postoperative INR and there was no significant difference
in terms of preoperative (P  .13) or postoperative INR
(P  .3181) between groups. INR was significantly lower
in group N compared to group C, as measured 30 minutes
(P  .0001), and 2 hours (P  .0001) after the operation
(Kruskal-Wallis ANOVA nonparametric test; Table IV).
Among patients in group N, 10 (41.67%) received one,
and 14 (58.33%) received both hemostatic drugs (antifi-
brinolytics and DDAVP), while in group C, 9 (29.03%)
received one, while 20 (64.53%) were treated with both
hemostatic drugs. There was no statistical difference be-
tween the groups regarding this treatment (P  .32).
Moreover, univariate andmultivariate analysis revealed that
therapy with antifibrinolytics and DDAVP had no signifi-
cant influence on survival. In 22 patients, we used a single
bolus dose of 5 mL of NovoSeven that was 50 to 76mg/kg
according to the patients’ body weight. In addition, there
was no significant influence of the dosage of the rVIIa used
in group N on the INR value improvement or on the
survival.
Outcome. Therapeutic benefit of all hemostatic mea-
sures, including therapy with rFVIIa was estimated by a
decrease in the postoperative amount of wound drainage,
normalization of INR, and a decreased need for inotrope
drugs and blood transfusions. The successful cessation of
bleeding was present in 21 of 24 patients (87.5%) who were
treated with rFVIIa, and in 9 of 31 patients (29.03%) in
group C (P  .001).
Finally, the mortality of these two groups was signifi-
cantly different; 3 patients (12.55%) from group N and 25
patients (80.65%) from group C died (P  .0001).
Of 3 patients (12.55%) in group N, one died intraop-
eratively (RAAA), when rFVIIa was not expected to have
any visible effect on nonsurgical hemorrhage, while 2 pa-
tients (both with TAAAs) had multiple organ failure syn-
drome (MOFS) due to hypoperfusion. and died in the first
postoperative day. Postmortem examination did not reveal
any evidence of acute thrombotic events in 2 of 3 cases.
The cause of death in 25 patients from group C was
myocardial infarction in 9 patients (36%), MOFS in 8
patients (32%), acute respiratory distress syndrome in 6
patients (24%), and renal failure in 2 patients (8%).
Univariate analysis showed that platelet transfusion, the
amount of postoperative blood loss, MOFS, and applica-
tion of rFVIIa were significantly associated with survival.
Multivariate analysis revealed that factors associated with
survival were postoperative blood loss, treatment with rFVIIa
(P  .001, odds ratio, 0.04; confidence interval, 95%
0.006-0.28), and MOFS (P  .05; odds ratio, 13.9; con-
fidence interval, 0.92-210.6).
The overall mortality rate after RAAA repair in our
hospital, in the period from 1995 to 2003 was 53%, while
mortality in group C, operated in the same time period, was
87%. On the other side, overall mortality in the period from
2003 to 2007 was 38%, while mortality in N group, oper-
ated in the same period of time, was 7.14%. tISCUSSION
The rFVIIa was introduced to the clinical practice in
980s and has been shown to be a highly effective hemo-
tatic agent in patients with hemophilia.25,26 Recent re-
orts on rFVIIa application in the cases of severe post-
raumatic bleeding or bleeding associated with different
urgical procedures suggest its efficacy even in patients
ithout pre-existing hemorrhagic diatheses.27-29 How-
ver, more liberal use of rFVIIa in vascular patients is
imited by a lack of randomized controlled trials on its
afety and efficacy, by absence of dosing guidelines and by
oorly defined indications.
Our results show that all patients had an increased value
f INR before the treatment with rFVIIa. According to the
ecent study, rotational thromboelastography contributed
ven more in revealing the cause of hemorrhage in order to
hoose adequate therapy; however, we did not use this
ethod until 2009 due to technical insufficiency of our
aboratory.30,31 Several studies showed that reversal or
apid decrease of INR value can be used as a parameter of
ffective treatment with rFVIIa, which is supported by our
wn results.32 Administration of rFVIIa correlated with
ormalization of INR and with clinical improvement.33,34
There is no consensus on the dosage of rFVIIa in
ascular patients. Moreover, there are special concerns in
ascular patients because of the higher exposure of tissue
actor in circulation, which may predispose them to the
reater incidence of adverse events. Therefore, Abshier et
l35 suggested a dose of 41 to 90 mg/kg, which is less than
he dose recommended in patients with hemophilia. Ac-
ordingly, we used a single bolus of 5 mL of NovoSeven,
hich is 50 to 76 mg/kg and only in 2 patients was an
dditional dose added, due to inadequate effect.6
According to published data, side effects of rFVIIa are
are.36-41 These were mainly inflammation and pain at the
ite of administration and skin irritation. Considering the
echanism of action rFVIIa, one should be aware of pos-
ible thromboembolic complications when using this drug.
s a side effect, thrombosis is most commonly reported in
atients who already had a tendency toward thrombotic
omplications due to conditions such as diabetes, malig-
ancy, or atherosclerotic cardiovascular diseases. In our
tudy, we did not observe these complications in clinical or
ostmortem examinations.
Reconstruction of TAAAs and urgent surgical treat-
ent of RAAAs are associated with massive blood loss.42,43
lood transfusions related to these procedures are associ-
ted with an increased incidence of complications, includ-
ng adult respiratory distress syndrome and MOFS.44,45 In
ur study, in the group of patients additionally treated with
FVIIa, incidence of these complications was significantly
ower. Multivariate analysis of our data revealed that factors
ontributed to outcome were treatment with rFVIIa and
ncidence of MOFS. We argue that significantly reduced
ostoperative blood loss and consequently lesser need for
ransfusion therapy contributed to a reduced incidence of
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and myocardial infarction.
Among patients included in the present study, there
was no significant difference in demographic, preoperative,
and postoperative data. There was a significant difference in
age between our two groups of patients; still multivariate
analysis showed that age was not significantly associated
with survival. In addition, there was a significant difference
in intraoperative platelet transfusions between the two
groups; however, this may be explained by the lack of
platelets in the Serbian transfusion service due to the eco-
nomical crisis that was affecting our national health system
in the 1990s. All patients had intractable bleeding and were
treated with the same hemostatic measures and agents.
Patients from group N differed since they were additionally
treated with rFVIIa, suggesting that this additional therapy
contributed to cessation of bleeding. The rFVIIa was used
as a “last option” in those patients in whom regular mea-
sures did not improve hemostasis and INR was showing
coagulation disorder.
There are several limitations of our study; the number
of patients in the control group could be greater, but all
patients with positive inclusion and negative exclusion cri-
teria operated on in our institute were analyzed. The
groups we compared were not parallel, as patients were
treated in different time periods. Since 2003, in our clinical
practice, we routinely use rFVIIa in patients with intracta-
ble surgical bleeding when conventional measures are in-
adequate and, therefore, we considered it ethically to offer
rFVIIa treatment to all of our patients with appropriate
indications. Therefore, the control group had to be col-
lected retrospectively. Additionally, groups are heteroge-
neous, consisting of a mixed population of patients with
RAAAs and TAAAs who had severe bleeding. We chose
patients with the same complication, regardless of the
performed surgical procedure. However, statistical analysis
showed that surgical procedure had no significant influence
on survival rate. One may argue that better survival rates of
patients in group N (treated between 2003 and 2008) may
be the consequence of better experience of the staff and
better technical amenities, which were not fully available in
the period when patients from group C were operated on
(1995-2003). Finally, it might be difficult to differentiate
surgical from nonsurgical bleeding. However, we believe
that all patients included in this study had nonsurgical
bleeding, as the bleeding was detected intraoperatively
during wound closing when possible surgical causes of
bleeding were already excluded and patients with normal
intraoperative hemostasis who had massive postoperative
bleeding were excluded from the study.
CONCLUSION
In conclusion, our findings suggest that rFVIIa may
play a role in controlling the intractable perioperative and
postoperative bleeding in surgical patients undergoing a
repair of RAAAs and TAAAs. Certainly, prospective ran-
domized trials are necessary to further confirm the efficacynd cost-effectiveness of rFVIIa in these patients.
We are grateful to Tamara Djuric, PhD, Laboratory for
adiobiology andMolecular Genetics, Institute of Nuclear
ciences “Vinca”, Belgrade, Serbia, for her valuable work in
he statistical analysis of data, and to Maja Kojovic, for her
ontribution in literal construction of this manuscript.
EFERENCES
1. Hyde JA, Chinn JA, GrahamTR. Platelets and cardiopulmonary bypass.
Perfusion 1998;13:389-407.
2. Stratmann G, Russell IA, Merrick SH. Use of recombinant factor VIIa
as a rescue treatment for intractable bleeding following repeated aortic
arch repair. Ann Thorac Surg 2003;76:2094-7.
3. McIlroy DR, Silvers AJ. Recombinant factor VIIa for life-threatening
bleeding in high-risk cardiac surgery despite full-dose aprotinin. Anesth
Analg 2004;99:27-30.
4. Isbister JP. Decision making in perioperative transfusion. Transfus
Apharesis Sci 2002;27:19-28.
5. Von Depka M. NovoSeven: mode of action and use in acquired hemo-
philia. Intensive Care Med 2002;(28 Suppl 2):S222-7.
6. Seremetis S. Dose optimization of recombinant factor VIIa in the
treatment of acute bleeding in haemophillia-associated inhibitors.
Blood Coagul Fibrinolysis 2003;14(Suppl 1):S29-30.
7. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic
bleeding with recombinant factor VIIa. Lancet 1999;354:1879.
8. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J,
Lynn M. Recombinant activated factor VII for adjunctive haemorrhage
control in trauma. J Trauma 2001;51:431-8; discussion 438-9.
9. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al.
Recombinant factor VIIa as adjunctive therapy for bleeding control in
severely injured patients: two parallel randomized, placebo-controlled,
double-blind clinical trials. J Trauma 2005;59:8-15; discussion 15-8.
0. Hendricks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff
MJ, van derMeer J. An effective treatment of severe intractable bleeding
after valve repair by one single dose of activated recombinant factor VII.
Anesth Analg 2001;93:287-9.
1. von Heymann C, Hotz H, Konertz W, Kox WJ, Spies C. Successful
treatment of refractory bleeding with recombinant factor VIIa after
redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth
2002;16:615-6.
2. Tobias JD. Synthetic factor VIIa to treat dilutional coagulopathy during
posterior spinal fusion in two children. Anesthesiology 2002;96:
1522-5.
3. Slappendel R, Huvers FC, Benraad B, Novàkova I, van Hellemondt
GG. Use of recombinant factor VIIa (NovoSeven) to reduce postoper-
ative bleeding after total hip arthroplasty in a patient with cirrhosis and
thrombocytopenia. Anesthesiology 2002;96:1525-7.
4. Manning BJ, Hynes N, Courtney DF, Sultan S. Recombinant factor
VIIa in the treatment of intractable bleeding in vascular surgery. Eur J
Vasc Endovasc Surg 2005;30:525-7.
5. Tawfick WA, Tawfik S, Hynes N, Mahendran B, Sultan S. Critical
bleeding in vascular surgery: expanding the indication of recombinant
activated factor VII. Vascular 2006;14:32-7.
6. Wahlgren CM, Swedenborg J. The use of recombinant activated factor
VII to control bleeding during repair of suprarenal abdominal aortic
aneurysm. Eur J Vasc Endovasc Surg 2003;26:221-2.
7. Liem AK, Biesma DH, Ernst SM, Schepens AA. Recombinant activated
factor VII for false aneurysm in patients with normal haemostatic
mechanisms. Thromb Haemost 1999;82:150-1.
8. Warren OJ, Alcock EM, Choong AM, Leff DR, Van Herzeele I, Darzi
AW, et al. Recombinant activated factor VII: a solution to refractory
haemorrhage in vascular surgery? Eur J Vasc Endovasc Surg 2008;35:
145-52.
9. Koncar IB, Savic´ N, Davidovic´ LB, Simic´ D, Markovic´ D, Sindjelic´ RB.
[Recombinant activated factor VII in the treatment of intractable
non-surgical bleeding following major vascular procedures. ] [Article in
Serbian] Srp Arh Celok Lek 2008;136:367-72.
33
3
3
3
3
3
4
4
4
4
4
4
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 4 Hoch 103720. Markovic´ M,Davidovic´ L,Maksimovic´ Z˘, Kostic´ D, Cinara I, Cvetkovic´
S, et al. Ruptured abdominal aortic aneurysm. Predictors of survival in
229 consecutive surgical patients. Herz 2004;29:123-9.
21. Crawford SE. Ruptured abdominal aortic aneurysm. J Vasc Surg 1991;
13:348-50.
22. Stainsby D,MacLennan S, Hamilton PJ. Management of massive blood
loss: a template guideline. Br J Anaesth 2000;85:487-91.
23. Donaldson MD, Seaman MJ, Park GR. Massive blood transfusion. Br J
Anaesth 1992;69:621-30.
24. Fakhry SM, Sheldon GF. Massive transfusion in the surgical patient. In:
Jeffries LC, BrecherME, editors. Massive Transfusion. Bethesda, Mary-
land: American Association of Blood Banks; 1994.
25. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two
hemophilia A patients with high-titer inhibitors. J Clin Invest 1983;71:
1836-41.
26. Hedner U. Recombinant factor VIIa: its background, development and
clinical use. Curr Opin Hematol 2007;14:225-9.
27. Martinowitz U, Michaelson M; Israeli Multidisciplinary rFVIIa Task
Force. Guidelines for the use of recombinant activated factor VII
(rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisci-
plinary rFVIIa Task Force. J Thromb Haemost 2005;3:640-8.
28. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T,
Kurth KH, et al. Effect of recombinant activated factor VII on periop-
erative blood loss in patients undergoing retropubic prostatectomy: a
double-blind placebo-controlled randomised trial. Lancet 2003;361:
201-5.
29. Busani S, Semeraro G, Cantaroni C, Masetti M, Marietta M, Girardis
M. Recombinant activated factor VII in critical bleeding after ortho-
topic liver transplantation. Transplant Proc 2008;40:1989-90.
30. Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA. The
predictive value of modified computerized thromboelastography and
platelet function analysis for postoperative blood loss in routine cardiac
surgery. Anesth Analg 2003;96:51-7.
31. Sørensen B, Ingerslev J. Thromboelastography and recombinant factor
VIIa-hemophilia and beyond. Semin Hematol 2004;41(1 Suppl 1):
140-4.
32. Planinsic RM, van der Meer J, Testa G, Grande L, Candela A, Porte RJ,
et al. Safety and efficacy of a single bolus administration of recombinant
factor VIIa in liver transplantation due to chronic liver disease. Liver
Transpl 2005;11:895-900. S
ability to control hemorrhage. Koncˇar et al reported no thrombo-
embolic complications in their historical control or treatment
g
E
b
c
T
a
s
o
a
t
c
g
r
c
i
o
p
a
i
d
n
c3. Sørensen B, Johansen P, Nielsen GL, Sørensen JC, Ingerslev J. Reversal
of the International Normalized Ratio with recombinant activated
factor VII in central nervous system bleeding during warfarin throm-
boprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrino-
lysis 2003;14:469-77.
4. Schreiber MA, Holcomb JB, Hedner U, Brundage SI, Macaitis JM,
Aoki N, et al. The effect of recombinant factor VIIa on noncoagulo-
pathic pigs with grade V liver injuries. J Am Coll Surg 2003;196:691-7.
5. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing
regimens and safety in patients with congenital and acquired factor VIII
or IX inhibitors. J Thromb Haemost 2004;2:899-909.
6. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion
medicine. Transfusion 2002;42:114-24.
7. Roberts HR. Recombinant factor VIIa (Novoseven) and the safety of
treatment. Semin Hematol 2001;38(4 Suppl 12):48-50.
8. Roberts HR. Clinical experience with activated factor VII: focus on
safety aspects. Blood Coagul Fibrinolysis 1998;9(Suppl 1):S115-8.
9. Peerlinck K, Vermylen J. Acute myocardial infarction following admin-
istration of recombinant activated factor VII (Novo Seven) in a patient
with haemophilia A and inhibitor. Thromb Haemost 1999;82:1775-6.
0. Guillet B, Pinganaud C, Proulle V, Dreyfus M, Lambert T. Myocardial
infarction occurring in a case of acquired haemophilia during the
treatment course with recombinant activated factor VII. Thromb Hae-
most 2002;88:698-9.
1. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thrombo-
embolic adverse events after use of recombinant human coagulation
factor VIIa. JAMA 2006;295:293-8.
2. Rott H, Trobisch H, Kretzschmar E. Use of recombinant factor VIIa,
Novo Seven, in the management of acute haemorrhage. Curr Opin
Anesthesiol 2004;17:159-63.
3. Cohen JR, Angus L, Asher A, Chang JB, Wise L. Disseminated intra-
vascular coagulation as a result of supraceliac clamping: implications for
thoracoabdominal aneurysm repair. Ann Vasc Surg 1987;1:552-7.
4. Spence RK, Carson JA. Transfusion decision-making in vascular sur-
gery: blood ordering schedules and the transfusion trigger. Semin Vasc
Surg 1994;7:76-81.
5. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII
(rFVIIa). Semin Thromb Hemost 2000;26:385-91.ubmitted Oct 2, 2009; accepted Jul 18, 2010.INVITED COMMENTARYJohn R. Hoch, MD, Madison, Wisc
In 1999, the US Food and Drug Administration approved the
use of rVIIa for the treatment of bleeding in patients with hemo-
philia A or B and inhibitors of factors VII and IX. Since then, rVIIa
has been increasingly used off-label to treat surgical patients with-
out hemophilia that have intractable bleeding. Koncˇar et al de-
scribe the largest case series of vascular patients treated with rVIIa.
Like numerous earlier case reports and case series, the current
article describes the use of rVIIa to decrease blood transfusion
requirements and correct coagulopathy after major operations
associated with serious nonsurgical bleeding.1,2 The current series
also highlights a significant survival advantage for patients treated
with rVIIa compared to a historical control group. Similarly, a
meta-analysis of case series analyzing the use of rVIIa in major
abdominal operations found a 73% mean reduction or cessation of
bleeding and a 53% mean probability of survival after administra-
tion of rVIIa.1
Activated factor VII (VIIa) is believed to complex with tissue
factor in the subendothelium at sites of injury, leading to the
activation of factors IX and X and the generation of thrombin.3
Because of its mechanism of action, there exists the potential for
thrombotic complications which must be balanced with rVIIa’sroup. A review of the Food & Drug Administration’s Adverse
vent Reporting System between 1999 and 2004 for thromboem-
olic adverse events (TAEs) with rVIIa, led the authors to con-
lude that there was a substantial risk of TAEs.4 The majority of
AEs occurred with the use of rVIIa for unlabeled indications, and
rterial thrombotic complications were the most common. A sub-
equent meta-analysis of case series calculated a mean probability
f 16.5% for thrombemboli associated with rVIIa use during
bdominal surgery.1 A recent meta-analysis of randomized con-
rolled trials comparing rVIIa to placebo found that TAEs oc-
urred in 8.6% of the rVIIa group compared to 6.4% in the placebo
roup.2 However, arterial TAEs occurred more frequently in the
VIIa group compared to placebo. Despite the lack of TAEs in the
urrent article, a review of the literature would suggest that an
ncreased risk of thrombotic complications is suspected that can
nly be ascertained by randomized controlled trials.
Koncˇar et al’s routine use of rVIIa for intractable bleeding in
atients treated for ruptured abdominal aortic aneurysms (RAAAs)
nd elective thoracoabdominal aortic aneurysms (TAAAs) resulted
n a significant reduction in mortality rate (13%), a significant
ecrease in transfusion requirement, and rapid correction of inter-
ational normalized ratio compared to their retrospective histori-
al control group. However, these results are not sufficient to
